This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Barry Brown, MD
Seattle Indian Health Board Seattle, Wash

JAMA. 1997;277(4):295.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In the design of their model evaluating cost vs benefit of the inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) schedule, Dr Miller and colleagues¹ state that the Delphi panel assumed that no immunodeficient persons receiving a vaccination will avoid vaccine-associated paralytic poliomyelitis (VAPP) by receiving 2 doses of IPV before OPV. Yet, in their review of 105 cases of VAPP, Nkowane et al² noted that, of the 11 immunodeficient recipients with VAPP, 3 contracted it on the third or fourth OPV dose. These data suggest a reduction of VAPP by 27% among immunodeficient recipients if the schedule of 2 IPV doses and 2 OPV doses is adopted. Were these data considered by the Delphi panel prior to design of the model? . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?